FIELD: biotechnologies.
SUBSTANCE: what is created is plasmid matrix C1M-BSI having nucleotide sequence SEQ ID NO: 1, size 4387 bp, molecular weight 2.8 MDa, containing target gene coding artificial polyepitope protein BSI-COV, providing synthesis of mRNA mRNA-BSI in vitro. Obtained mRNA mRNA-BSI, having nucleotide sequence SEQ ID NO: 2, length 1532 bp, coding bsi-cov gene and having 5'- and 3'-UTR, Kozak consensus sequence, 7-methylguanosine cap by 5'-end and a polyadenosine (polyA) tail for 3'-end. When administered into laboratory animals, said mRNA induces humoral and cell-mediated immune response.
EFFECT: creating the universal, safe and effective polyepitope mRNA-vaccine able to induce a specific cytotoxic and T-helper response against various strains of SARS-CoV-2 virus.
2 cl, 9 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
| CONJUGATE OF THE RECEPTOR-BINDING DOMAIN (RBD) PROTEIN OF SARS-CoV-2 SURFACE GLYCOPROTEIN S WITH POLYGLUCIN-SPERMIDINE (PGS) POLYMER AND VACCINE COMPLEX AGAINST CORONAVIRUS INFECTION COVID-19 BASED ON THE SPECIFIED CONJUGATE AND PLASMID DNA PVAX-RBD | 2022 |
|
RU2781294C1 |
| PLASMID DNA CARTRIDGE pVAX-C3-polyA, PLASMID DNA MATRIX pVAX-C3-RBD-polyA FOR mRNA SYNTHESIS AND POLYNUCLEOTIDE VACCINE AGAINST SARS-CoV-2, WHICH IS MOLECULES mRNA-C3-RBD-polyA WHICH INDUCE SARS-CoV-2-SPECIFIC ANTIBODIES | 2024 |
|
RU2839841C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| METHOD OF OBTAINING BACTERIAL PRODUCER OF RECOMBINANT NC NUCLEOCAPPSID PROTEIN OF SARS-CoV-2 VIRUS | 2023 |
|
RU2812347C1 |
| RECOMBINANT STRAIN SEN-SDELTA(M) OF SENDAI VIRUS, PRODUCING S-PROTEIN SARS-CoV-2 AND USED TO PRODUCE INTRANASAL VACCINE AGAINST COVID-19 | 2024 |
|
RU2837536C1 |
| ARTIFICIAL ECTOS_SC2 GENE ENCODING AN ECTODOMAIN OF THE SARS-COV-2 CORONAVIRUS S GLYCOPROTEIN WITH A C-TERMINAL TRIMERIZATION DOMAIN, A RECOMBINANT PLASMID PSTEM-RVSV-ECTOS_SC2, WHICH PROVIDES EXPRESSION OF THE ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-ECTOS_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733834C1 |
